CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 395 enrolled
Drug / intervention
Glyburide +1 moredrug
Likely dose
Glyburide 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00744965
NCT00744965Phase 4Completed

A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

University of Texas Southwestern Medical Center·interventional·Posted Sep 1, 2008·Updated Mar 12, 2020

In Brief

A Phase 4 clinical trial evaluating Glyburide and Placebo for Mild Gestational Diabetes. Completed, enrolled 395 participants across 1 site.

Detailed Summary

This is a randomized prospective trial which addresses the question of whether use of an oral hypoglycemic agent as an adjunct to diet therapy in women with mild gestational diabetes will result in achieving euglycemia in a shorter period of time and, in turn, result in less frequent maternal and neonatal morbidities. This study is designed to test the hypothesis that in women with mild GDM, use of Glyburide in addition to diet and nutritional counseling lowers mean infant birth weight by 200 grams as compared with diet and nutritional counseling alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 1, 2008
Enrollment StartSep 16, 2008
Primary CompletionJan 1, 2013
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.8 years ago

Interventions

Glyburidedrug

Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.

Placebodrug

Sham dose adjustments of the placebo will be made.